Compare SHO & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHO | OCUL |
|---|---|---|
| Founded | 1995 | 2006 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | N/A | N/A |
| Metric | SHO | OCUL |
|---|---|---|
| Price | $9.36 | $7.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $9.50 | ★ $22.56 |
| AVG Volume (30 Days) | 2.5M | ★ 6.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.85 | $10.00 |
| Revenue Next Year | $3.56 | $102.68 |
| P/E Ratio | $973.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.45 | $5.79 |
| 52 Week High | $11.51 | $16.44 |
| Indicator | SHO | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 23.56 |
| Support Level | $8.98 | $8.63 |
| Resistance Level | $9.46 | $9.34 |
| Average True Range (ATR) | 0.24 | 0.64 |
| MACD | 0.05 | -0.09 |
| Stochastic Oscillator | 87.66 | 17.17 |
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.